Skip to content

5-MeO-DMT: all studies

Page 87 of 110: studies 861 to 870 of 1,096, newest first. Back to the 5-MeO-DMT overview

Research

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.

European Neuropsychopharmacology May 20, 2016 Anna Rickli, Olivier D. Moning, Marius C. Hoener et al. 374 citations

The present study investigated interactions between the novel psychoactive tryptamines DiPT, 4-OH-DiPT, 4-OH-MET, 5-MeO-AMT, and 5-MeO-MiPT at monoamine receptors and transporters compared with the classic hallucinogens lysergic acid diethylamide (LSD), psilocin, N,N-dimethyltryptamine (DMT), and mescaline. We investigated binding affinities at human monoamine receptors and determined...

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.

The Lancet Psychiatry April 5, 2016 Michael C Mithoefer, Charles S. Grob, Timothy D Brewerton 237 citations

4-phosphorloxy-N,N-dimethyltryptamine (psilocybin) and methylenedioxymethamfetamine (MDMA), best known for their illegal use as psychedelic drugs, are showing promise as therapeutics in a resurgence of clinical research during the past 10 years. Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer with anxiety. MDMA is showing encouraging results as...

Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans

European Neuropsychopharmacology March 26, 2016 Marta Valle, Ana Maqueda, Mireia Rabella et al. 175 citations

Ayahuasca is an Amazonian psychotropic plant tea typically obtained from two plants, Banisteriopsis caapi and Psychotria viridis. It contains the psychedelic 5-HT2A and sigma-1 agonist N,N-dimethyltryptamine (DMT) plus β-carboline alkaloids with monoamine-oxidase (MAO)-inhibiting properties. Although the psychoactive effects of ayahuasca have commonly been attributed solely to agonism at the...

Ayahuasca: Pharmacology, neuroscience and therapeutic potential

Brain Research Bulletin March 11, 2016 Elisabet Domínguez‐clavé, Joaquim Soler, Matilde Elices et al. 220 citations

Ayahuasca is the Quechua name for a tea obtained from the vine Banisteriopsis caapi, and used for ritual purposes by the indigenous populations of the Amazon. The use of a variation of the tea that combines B. caapi with the leaves of the shrub Psychotria viridis has experienced unprecedented expansion worldwide for its psychotropic properties. This preparation contains the psychedelic 5-HT2A...

Presence and evolution of a new psychoactive tryptamines branch

European Psychiatry March 1, 2016 Á. Palma Conesa, L. Galindo Guarín, M. Grifell Guàrdia et al.

Introduction New psychoactive substances (NPS) are substances that have recently appeared on the market and are not under international control. NPS use is experiencing an unprecedented increase. DiPT, 4-HO-DiPT and 4-AcO-DiPT are new psychoactive tryptamines and their effects may differ from those of other psychoactive tryptamines. Objective To explore the presence of DiPT, 4-HO-DiPT and...

A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience.

Frontiers in Pharmacology 2016 Andrew R. Gallimore, Rick J. Strassman 51 citations

The state of consciousness induced by N,N-dimethyltryptamine (DMT) is one of the most extraordinary of any naturally-occurring psychedelic substance. Users consistently report the complete replacement of normal subjective experience with a novel "alternate universe," often densely populated with a variety of strange objects and other highly complex visual content, including what appear to be...

Effects of Long-Term Ayahuasca Administration on Memory and Anxiety in Rats

PLoS One December 30, 2015 Vanessa Manchim Favaro, Maurı́cio Yonamine, Juliana Carlota Kramer Soares et al. 33 citations

Ayahuasca is a hallucinogenic beverage that combines the action of the 5-HT2A/2C agonist N,N-dimethyltryptamine (DMT) from Psychotria viridis with the monoamine oxidase inhibitors (MAOIs) induced by beta-carbonyls from Banisteriopsis caapi. Previous investigations have highlighted the involvement of ayahuasca with the activation of brain regions known to be involved with episodic memory,...

Glokalizace ayahuasky v ČR a možnosti jejího terapeutického využití v místních podmínkách

Anthropologia integra December 15, 2015 Miroslav Horák, Romana Lukášová, Šárka Vosáhlová 6 citations

Z ayahuasky, klíčového prvku tradiční domorodé medicíny peruánské Amazonie, se stal globální fenomén. Sezení, během něhož je užívána tato psychoaktivní látka, lze v současné době absolvovat nejen v prostředí jihoamerického deštného pralesa, ale také v České republice. Vzhledem k tomu, že je v ČR ayahuasca pro svůj obsah N, N-dimethyltriptaminu dle nařízení vlády č. 463/2013 Sb., O seznamech...

Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities

Psychopharmacology November 27, 2015 Joaquim Soler, Matilde Elices, Alba Franquesa et al. 212 citations

BackgroundAyahuasca is a psychotropic plant tea used for ritual purposes by the indigenous populations of the Amazon. In the last two decades, its use has expanded worldwide. The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus β-carboline alkaloids with monoamine-oxidase-inhibiting properties. Acute administration induces an introspective dream-like...

Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class.

Toxicology Letters November 17, 2015 Julia Dinger, Campbell Woods, Simon D. Brandt et al.

New psychoactive substances (NPS) are not tested for their cytochrome P450 (CYP) inhibition potential before consumption. Therefore, this potential was explored for tryptamine-derived NPS (TDNPS) including alpha-methyl tryptamines (AMTs), dimethyl tryptamines (DMTs), diallyl tryptamines (DALTs), and diisopropyl tryptamines (DiPTs) using test substrates preferred by the Food and Drug...